Lilly’s Jaypirca Approved for Leukemia Treatment

Eli Lilly's drug Jaypirca has been approved by the FDA as a first-line therapy for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma. This approval is expected to significantly impact patient treatment options.